Background: A 32-base pair (bp) deletion mutation in the betachemokine receptor CCR.5 gene has been associated with resistance against human immunodeficiency virus type 1 (HIV-1) infection and disease. Large-scale studies conducted among Caucasians indicate that individuals who are homozygous for this deletion mutation (A32/A32) are protected against HIV-I infection despite multiple high-risk exposures, whereas CCRS/ A32 heterozygotes have a slower progression to acquired immunodeficiency syndrome (AIDS).
Entry of human immunodeficiency virus type 1 (HIV-l) into target cells requires the binding of the external envelope glycoprotein gp120 to both the CD4 molecule and one of several chemokine receptors, recently discovered to function as coreceptors.l-' T-cell line-tropic HIV-l strains utilize the a-chemokine receptor CXCR4,' whereas the B-chemokine receptor 5 (CCR5), which is expressed on monocytes/macrophages, 'I' cells, and granulocyte precursors, is the key cofactor for macrophage-tropic HIV-l strainszm6 which predominate during the asymptomatic phase of infection.
A 32-base pair (bp) deletion mutation (A32) within the second extracellular loop-encoding region of the CCRS gene, which results in a truncated, nonfunctional protein, has been associated with relative resistance to HIV-l infection and slower progression to acquired immunodeficiency syndrome (AIDS).'-" Specifically, A32/A32 homozygotes are protected against acquisition of HIV-l by the mucosal route despite high-risk exposure, whereas disease progression among CCR5/A32 heterozygotes occurs more slowly.
Among Caucasians, the genotype frequencies of CCR5/A32 heterozygosity and A32/A32 homozygosity are 16 to 35% and 1.0 to 3.6%, respectively.7-9z11 Limited information is available on the A32 allele frequency among non-Caucasian populations.7,9~12-15 To address this issue, the authors developed a polymerase chain reaction (FCR)-based assay to determine the genotype and allele frequencies of this CCR5 polymorphism in nearly 2000 blood samples collected from various populations, particularly those in Asia and the circum-Pacific region.
MATERIALS AND METHODS

Study Population
Blood samples, collected from 1980 to 1997, from 1912 individuals (1077 HIV-l-infected and 835 uninfected) belonging to various ethnic groups were studied: 187 HIV-1seropositive (48 male and 139 female) and 176 HIV-1-seronegative (2 male and 174 female) Caucasians from Hawaii; 303 HIV-l-infected Puerto Rican Hispanics; 150 Africans from Uganda; 606 Asians (279 Vietnamese, 128 Chinese, 109 Japanese, 42 Indian, 39 Filipino, 9 Korean); and 490 Pacific Islanders (253 Polynesians/part-Polynesians from Hawaii, 216 Melanesians from New Britain, and 21 Micronesians from Guam) with or without HIV-l infection. Samples were collected in conjunction with participation in clinical trials or other studies, as in the HIV-l sentinel surveillance program in Vietnam and the longitudinal registry for cervical and ovarian cancer among women in Hawaii. Demographic data, retrieved by coded identifiers, were provided by the respective study coordinators.
Genomic DNA Extraction
Extraction of genomic DNA from peripheral blood mononuclear cells (PBMC), huffy coat samples, or whole blood blotted onto filter paper was performed in a biosafety laminar-flow cabinet. For the former, PBMC pellets were resuspended in 50 to 250 yL of cell lysis buffer containing 1 X PCR buffer, 2.5 mM MgCl,, 0.5% NP-40, 0.5% Tween-20, and 120 pg/mL proteinase K. Mixtures were then incubated at 56"~ for 60 minutes, heated at 100°C for 10 minutes, and stored at 4°C for later use. DNA extraction from buffy coat samples was accomplished using a commercially available kit (Promega, Madison, WI), and extraction from filter paper-blotted blood samples, collected from HIV-l-infected individuals in the People's Republic of China and Vietnam, was performed according to a previously reported technique. 16 Briefly, filter paper-blotted blood samples were minced with sterile scissors and transferred to a 1.5 mL Eppendo@centrifuge tube (Brinkmann Instruments Inc., Wesbury, NY) containing 300 p,L of 100 mM NaCl, 10 mM Tris-HCl (pH 8.0) 75 kg proteinase K, 0.5% sodium dodecyl sulfate, and 1 mM ethylenediaminetetraacetic acid. Following incubation with occasional gentle inversion at 56'C for 1.5 hour, genomic DNA was isolated using the phenol-chloroform method with ethanol precipitation.
CCR5 Genotyping by PCR
A targeted region of the CCR5 gene flanking the 32-bp deletion was amplified by PCR, using an oligonucleotide primer pair designed to discriminate between CCR5 alleles without restriction endonuclease digestion: forward, 5'-GTCTCTCCCAGGAATCATCTTTACCAGATCTC-3'; reverse, 5'-'ITAGGATICCCGAGTAGCAGATGACCATGACA-3'. Each PCR was conducted in a final volume of 50 FL containing 0.2 to 0.5 i.i,g template DNA, 1 X PCR buffer, 200 PM each dN= 1 mM MgCl,, 1.25 U Themus aquaticus DNA polymerase (Perkin-Elmer Corporation, Norwalk, CT), and 50 nM each primer. Thermocycling conditions consisted of 45 cycles with an initial denaturation at 94'C for 5 minutes, followed by denaturation at 94°C for 1 minute, annealing at 60"~ for 1 minute, and extension at 72°C for 1 minute. The mutated and unmutated alleles appeared as 147-bp and 179-bp amplicons, respectively, which were easily distinguishable by ethidium bromidestained gel electrophoresis using 3% NuSieve agarose (FMC BioProducts, Rockland, ME).
To minimize sample carryover, all specimens and reagents were handled in a BSL-2 cabinet or UV-mounted PCR Workstation (C.B.S. Scientific Co., Del Mar, CA). Reagents were dispensed using aerosol-resistant pipette tips. Pre-PCR, thermocycling and post-PCR manipulations were performed in physically separated cubicles. Additionally, two negative controls were used in each PCR run.
Validation of CCR5 Genotyping Assay
Beverly, MA), incubated for at least 2 hours at 37°C for PstI and at 50°C for ApoI. Since the single recognition To verify that the 147-bp amplified segment was trun-site of ApoI was within the 32-bp deletion, the presence cated because of the 32-bp deletion, randomly selected of the deletion mutation resulted in ApoI resistance and PCR amplicons were analyzed by restriction endo-P&I sensitivity. nuclease digestion, using two enzymes, ApoI and P&I, To further confirm the specifkity of the PCR-based which made single cuts within and upstream of the 32-CCRS assay, representative PCR products were cloned bp deletion, respectively ( Figure 1, A and B) . Each diges-using the TA cloning kit (Invitrogen, San Diego, CA), and tion was performed in a 3O+L volume containing the clones were sequenced in both directions on an autoappropriate digestion buffer, 10 PL PCR amplicon, and mated sequencer (model 373A, Applied Biosystems Inc., 5 units of either ApoI or PstI (New England Biolabs, Inc., Foster City, CA) using the same oligonucleotides 
RESULTS
To facilitate rapid genetic screening for the A32 allele in various ethnic populations, a PCR-based assay was established using an oligonucleotide primer pair designed to identify CCR5 genotypes without restriction enzyme analysis. Two PCR products, 179 bp and 147 bp in length, representing the CCR5 wild-type and A32 mutated alleles, respectively, were easily discriminated by agarose gel electrophoresis (see Figure 1 ). Analyses of the two fragments by restriction endonuclease digestion and by cloning and DNA sequencing verified the 32-bp deletion within the shorter amplified product. Specifically, the 147bp product was resistant to ApoI digestion, but sensitive to PstI (see Figure 1 ,A and B), and DNA sequencing indicated that bases 580 to 611 of the CCR5 coding region were missing in the 147-bp amplicon (d&a not shown). Among Caucasians, the overall frequency of the heterozygous genotype (CCR5/A32) was 16.8% (61/363), with a A32 allele frequency of 9.2% (67/726). No difference was found in the CCR5/A32 genotype frequency between HIV-l-infected (32/187 [ 17.1%]) and HIV-l-uninfected (29/176 [16.5%]) Caucasians (Table 1 ). By contrast, the frequency of the homozygous genotype (A32/A32) was 1.7% (3/176) among HIV-l-uninfected Caucasians and nil (O/187) among HIV-l-infected Caucasians (see Table 1 ).
Four Caucasians who possessed the heterozygous genotype (CCR5/A32) were long-term survivors (infected for 11 to 13 y), and 13 other individuals (10 Caucasians, 1 Hispanic, 1 Japanese, and 1 Pacific Islander) infected with HIV-l for 13 to 17 years were neither heterozygous nor homozygous for the 32-bp deletion mutation. Some of these 13 individuals had relatively high CD4 counts (>500 cells/mm3) and low plasma viral loads (<lo00 copies/ml).
Analysis of the HIV-l-infected Puerto Rican Hispanics indicated a CCR5/A32 genotype frequency of 5.6% (17/303) (see Table 1 ) and a A32 allele frequency of 2.8% (17/606). By contrast, none of 150 Africans from Uganda possessed the A32 allele. Also, irrespective of their HIVl-infection status, all of the 606 Asians were homozygous for the wild-type or unmutated allele (CCR5KCR5). Similarly, among individuals of Polynesian, Micronesian, and Melanesian descent with no known European Caucasian admixture, the A32 allele was not found (see Table 1 ). A A32 allele frequency of 1.8% (9/506) and a CCR5/A32 genotype frequency of 3.6% (9/253) was found among Hawaiians, but all nine CCR5/A32 heterozygous Hawaiians had Caucasian parents or grandparents.
DISCUSSION
The discovery of a 32-bp deletion mutation in the CCR5 gene marks a significant step toward understanding the critical relation between chemokine receptors and HIV-l entry and subsequent disease progression. Genotypic analysis of this 32-bp deletion mutation among individuals of European Caucasian descent indicates that approximately 1 to 3% carry two defective alleles and 15 to 30% are heterozygous. 7-9,11 Since polymorphisms of chemokine receptor genes appear to result in differential resistance and susceptibility to HIV-l disease progression, understanding the allele frequencies of the CCR5 gene 32-bp deletion mutation in various ethnic populations may provide insights into the evolution of the defective allele, and in designing effective chemotherapeutic strategies directed against modulating the HIV-l-CCR5 interaction.
Using a rapid PCR-based assay, nearly 2000 DNA samples from Caucasians, Puerto Rican Hispanics, Africans, Asians, and Pacific Islanders were examined for the A32 Frequencies are shown in parentheses, A32/A32 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 3 (0.017) 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) allele. The approximately 17% CCR5/A32 heterozygosity rate detected among HIV-l-infected and uninfected Caucasians and the A32/A32 homozygosity rate of 1.7% in HIV-1-seronegative Caucasians in this study fell within the range reported previously for Caucasian populations.7-9z11 Despite the apparent resistance afforded by the CCR5 gene 32-bp deletion mutation, protection against HIV-1 infection is not absolute, as evidenced by reports of HIV-l infection among A32/A32 homozygates."-'" Thus far, however, acquisition of HIV-l infection in such individuals has been by the parenteral, rather than mucosal route, suggesting utilization of the CXCR4 coreceptor by dual-tropic strains of HIV-1 among infected A32/A32 homozygotes. A CCR5/A32 heterozygous genotype frequency of 6.7% has been reported previously for Hispanics living in the United States who trace their heritage to Mexico as well as to Central and South America.12 In the present study, a similar overall low-level CCR5/A32 heterozygosity of 5.6% was found among Puerto Ricans. Although Puerto Ricans are generally classified as Hispanics, their genetic composition is rather more complex and diverse, with admixture of Caucasian, Taino (and possibly Caribe) Indian, and African traits to varying degrees. In this regard, albeit to a lesser extent, the low A32 allele frequency among Hawaiians can be accounted for by recent Caucasian gene flow or admixture.
Not unexpectedly, CCR5/A32 heterozygosity was found among several long-term survivors. However, many more individuals infected with HIV-1 for more than 13 years and having relatively high CD4 counts and low plasma viral loads did not possess the A32 allele, indicating that polymorphisms other than the CCR5 gene 32-bp deletion mutation may account for slower progression to AIDS in such individuals. Specifically, a G to A nucleotide substitution at position 190 in the CCR2 gene results in a V to I change at position 64 of the CCR2 protein (CCR2-64l), and this point mutation appears to be operative in delayed progression to AIDS.*'-** In addition, a CCR5 gene mutation at position 303 (M303) from T to A has recently been identified to be an accomplice in conferring resistance to HIV-l infection. 23 The M303 mutation introduced a premature stop codon in the CCR5 gene, which results in the loss of the expression of a functional coreceptor. On the other hand, individuals with overproduction of beta-chemokines appear to resist HIV-1 infection, even in the absence of such polymorphisms in the CCR5 or CCR2 gene.** Inability to detect the A32 allele in HIV-l-infected and -uninfected Asian populations in the present study is consistent with previously published reports based on smaller numbers of individuals.7,9x14,1j However, the absence of the CCR5 gene 32-bp deletion mutation among Asians, as well as in Polynesian, Micronesian, and Melanesian populations, does not preclude, in such ethnic groups, the existence of other polymorphisms of chemokine receptor genes associated with slower progression to AIDS. For example, the extraordinarily high frequencies of the SDP13'A allele among non-Austronesian highlanders of Papua New Guinea and aboriginal populations of Australia warrants careful clinical correlation.zs
